Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for Androgenic Alopecia
NCT05456087Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Countries
- 1
- Sponsor
- Zel Skin & Laser Specialists
- Modality
- Recombinant Proteins and Enzymes
- Conditions
- androgenetic alopecia (AGA)
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in androgenetic alopecia (AGA), sponsored by Zel Skin & Laser Specialists. Primary endpoints: Changes from baseline in hair count per cm2 at Day 270, Changes from baseline in sum of hair width per cm2 at Day 270 and 5 more. Started Aug 2022; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Single treatment with Xeomin
Single session of Xeomin injections into the scalp
03
Endpoints
Primary
Changes from baseline in hair count per cm2
Changes from baseline in sum of hair width per cm2
Changes from baseline in Terminal:Vellus ratio
Changes from baseline in Average hairs per follicular unit
Changes from baseline in Average hair width
Secondary
Change from baseline in balding scalp hair recovery assessed by study investigator
Change from baseline in balding scalp hair recovery assessed by study participant
Beyond the preview
Go deeper on NCT05456087.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456087.